Atossa Therapeutics Inc   (ATOS)
Other Ticker:  
Price: $0.7598 $0.02 2.247%
Day's High: $0.7699 Week Perf: -6.16 %
Day's Low: $ 0.72 30 Day Perf: 13.4 %
Volume (M): 245 52 Wk High: $ 1.39
Volume (M$): $ 186 52 Wk Avg: $0.80
Open: $0.73 52 Wk Low: $0.50

 Market Capitalization (Millions $) 96
 Shares Outstanding (Millions) 126
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -42
 Capital Exp. (TTM) (Millions $) 0

Atossa Therapeutics Inc
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington that is primarily focused on developing innovative therapies that can prevent and treat breast cancer, as well as other medical conditions that are related to breast health. The company's mission is to improve the lives of patients by creating new treatments that are safe, effective, and patient-friendly.

Atossa Therapeutics has a number of proprietary products and technologies that it is developing for breast cancer and other indications. One of the company's flagship products is Endoxifen, which is a potent selective estrogen receptor modulator (SERM) that can be used to reduce the risk of developing breast cancer. Endoxifen has shown promising results in early-stage clinical trials, and the company is currently conducting more comprehensive clinical trials to evaluate its safety and efficacy.

In addition to Endoxifen, Atossa Therapeutics has also developed a range of other products that are designed to treat breast cancer and improve breast health. These products include:

- Topical Endoxifen: This is a topical form of Endoxifen that can be applied directly to the breast tissue. It is being developed for use in women who have been diagnosed with precancerous breast lesions or who are at high risk of developing breast cancer.
- Oral Endoxifen: This is an oral form of Endoxifen that can be taken by women who have been diagnosed with breast cancer or who are at high risk of developing the disease. It is currently in clinical trials to evaluate its safety and efficacy.
- Immunotherapies: Atossa Therapeutics is also developing a range of immunotherapies that can be used to treat breast cancer. These therapies are designed to stimulate the body's immune system to target and eliminate cancer cells.
- Breast Health Products: The company has also developed a range of products that are designed to improve breast health and reduce the risk of breast cancer. These products include a breast pump and a diagnostic device that can be used to detect breast cancer at an early stage.

Overall, Atossa Therapeutics is a leader in the development of innovative therapies for breast cancer and other breast health-related conditions. The company's proprietary products and technologies show great promise in the fight against breast cancer, and its ongoing clinical trials are expected to provide important insights into the safety and efficacy of these products.

   Company Address: 107 Spring Street Seattle 98104 WA
   Company Phone Number: 588-0256   Stock Exchange / Ticker: NASDAQ ATOS
   ATOS is expected to report next financial results on March 21, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com